Ranbaxy Laboratories inks in-licensing pact with Gilead Sciences

03 Aug 2012 Evaluate

Ranbaxy Laboratories has entered into an in-licensing agreement with Gilead Sciences to promote access to high quality, low cost generic versions of Gilead’s HIV medicine emtricitabine in developing countries, including single tablet regimes containing emtricitabine and fixed close combinations of emtricitabine co-formulated with other Gilead IIIV medicines.

Under the new agreement, Gilead will provide a technology transfer for the manufacture of emtricitabine, together with funding to assist with investment in process improvements to reduce manufacturing costs.

Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.

Peers
Company Name CMP
Sun Pharma Inds. 1806.35
Dr. Reddys Lab 1274.90
Cipla 1512.40
Zydus Lifesciences 923.60
Lupin 2079.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×